Moderna significantly exceeded first-quarter revenue expectations driven by a spike in international vaccine sales. Despite the top-line growth, the company posted a substantial net loss, weighing on share price.
- Q1 revenue reached $389 million, up from $108 million YoY
- Revenue exceeded analyst estimates of $236.4 million
- Company reported a net loss of $1.34 billion
- Earnings per share (EPS) loss stood at $3.40
- International vaccine demand served as the primary growth catalyst
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.